Medical progress: Pneumocystis pneumonia

New England Journal of Medicine

Volumn 350, Issue 24, 2004, Pages 2487-2498+2533

  Thomas Jr , Charles F ^a   Limper, Andrew H ^a,b,c  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; PENTAMIDINE; PYRIMETHAMINE; ANTIINFECTIVE AGENT; CYTOKINE;

ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DRUG DOSE REGIMEN; DRUG TARGETING; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENE MUTATION; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION CONTROL; INFECTION PREVENTION; INFLAMMATION; NONHUMAN; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; TABLET FORMULATION; VIRUS GENE; VIRUS MUTATION; VIRUS TRANSMISSION; AIDS RELATED COMPLEX; CYTOLOGY; IMMUNOLOGY; LUNG ALVEOLUS; MACROPHAGE; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PNEUMOCYSTIS JIROVECI;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CYTOKINES; HUMANS; MACROPHAGES; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; PULMONARY ALVEOLI; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 2942625674     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra032588     Document Type: Review

References (113)

1. HIV/AIDS surveillance supplemental report. Vol. 9. No. 3. Atlanta: Centers for Disease Control and Prevention, 2003:1-20.
2. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-107. [Erratum, Clin Infect Dis 2002;34:1293.]
3. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-107. [Erratum, Clin Infect Dis 2002;34:1293.]
4. Delanoë P, Delanoë M. Sur les rapports des kystes de Carini du poumon des rats avec le Trypanosoma Lewisi. C Acad Sci 1912;155:658-60.
5. Chagas C. Nova tripanozomiaze humana: estudo sobre a morfolojia e o evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1909;1:159-218.
6. Carinii A. Formas de eschizogonia do Trypanozoma lewisi. Commun Soc Med Sao Paolo 1910;16:204.
7. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334:519-22.
8. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
9. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-78.
10. Limper AH, Offord KP, Smith TF, Martin WJ II. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140:1204-9.
11. Randall Curtis J, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2000;162:393-8.
12. Sepkowitz, KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832-7.
13. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:513.
14. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998;113:1215-24.
15. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987;91:323-7.
16. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997;169:967-75.
17. Cushion MT, Beck JM. Summary of Pneumocystis research presented at the 7th International Workshop on Opportunistic Protists. J Eukaryot Microbiol 2001;48:Suppl:101S-105S.
18. Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996;124:585-99.
19. Bigby TD. Diagnosis of Pneumocystis carinii pneumonia: how invasive? Chest 1994;105:650-2.
20. Armbruster C, Pokieser L, Hassl A. Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients: comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase chain reaction. Acta Cytol 1995;39:1089-93.
21. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988;318:589-93.
22. Ortona E, Margutti P, De Luca A, et al. Non specific PCR products using rat-derived Pneumocystis carinii dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples. Mol Cell Probes 1996;10:187-90.
23. Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet 1991;337:1378-9.
24. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol 1997;35:830-5.
25. Tamburrini E, Mencarini P, Visconti E, et al. Detection of Pneumocystis carinii DNA in blood by PCR is not of value for diagnosis of P. carinii pneumonia. J Clin Microbiol 1996;34:1586-8.
26. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995;108:415-8.
27. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 2003;361:1267-8.
28. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
29. The National Institute of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990;323:15004.
30. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002;4:95-103.
31. Lundgren B, Elvin K, Rothman LP, Ljungstrom I, Lidman C, Lundgren JD. Transmission of Pnemocystis carinii from patients to hospital staff. Thorax 1997;52:422-4.
32. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001;39:3877-82.
33. Vargas SL, Ponce CA, Gigliotti F, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000;38:1536-8.
34. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982;145:842-8.
35. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003;187-9018.
36. Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003;9:132-4.
37. Helweg-Laxren J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999;354:1347-51.
38. Takahashi T, Hosoya N, Endo T, et al. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol 2000;38:3161-4.
39. Nahimana A, Rabodonirina M, Helweg-Larsen J, et al. Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia. Emerg Infect Dis 2003;9:864-7.
40. Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001;358:545-9.
41. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32:855-61.
42. Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993;61:2886-90.
43. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891-6.
44. Hughes WT. Pneumocystis carinii vs. Pneumocystis jiroveci: another misnomer (response to Sainger et al.). Emerg Infect Dis 2003;9:276-9.
45. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998;113:1225-9.
46. Matsumoto Y, Yoshida Y. Sporogony in Pneumocystis carinii: synaptonemal complexes and meiotic nuclear divisions observed in precysts. J Protozool 1984;31:420-8.
47. Itatani CA, Marshall GJ. Ultrastructural morphology and staining characteristics of Pneumocystis carinii in situ and from bronchoalveolar lavage. J Parasitol 1988;74:700-12.
48. Haidaris PJ, Wright TW, Gigliotti F, Fallon MA, Whitbeck AA, Haidaris CG. In situ hybridization analysis of developmental stages of Pneumocystis carinii that are transcriptionally active for a major surface glycoprotein gene. Mol Microbiol 1993;7:647-56.
49. Wyder MA, Rasch EM, Kaneshiro ES. Quantitation of absolute Pneumocystis carinii nuclear DNA content: trophic and cystic forms isolated from infected rat lungs are haploid organisms. J Eukaryot Microbiol 1998;45:233-9.
50. Gigliotti F, Stokes DC, Cheatham AB, Davis DS, Hughes WT. Development of murine monoclonal antibodies to Pneumocystis carinii. J Infect Dis 1986;154:315-22.
51. Gigliotti F, Ballou LR, Hughes WT, Mosley BD. Purification and initial characterization of a ferret Pneumocystis carinii surface antigen. J Infect Dis 1988;158:848-54.
52. Vuk-Pavlovic Z, Standing JE, Crouch EC, Limper AH. Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A. Am J Respir Cell Mol Biol 2001;24:475-84.
53. O'Riordan DM, Standing JE, Limper AH. Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun 1995;63:779-84.
54. Linke MJ, Cushion MT, Walzer PD. Properties of the major antigens of rat and human Pneumocystis carinii. Infect Immun 1989;57:1547-55.
55. Lundgren B, Koch C, Mathiesen L, Nielsen JO, Hansen JE. Glycosylation of the major human Pneumocystis carinii surface antigen. APMIS 1993;101:194-200.
56. Kovacs JA, Powell F, Edman JC, et al. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem 1993;268:6034-40.
57. Stringer JR, Keely SP. Genetics of surface antigen expression in Pneumocystis carinii. Infect Immun 2001;69:627-39.
58. Gigliotti F. Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii. J Infect Dis 1992;165:329-36.
59. Kovacs JA, Halpern JL, Lundgren B, Swan JC, Parrillo JE, Masur H. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis 1989;159:60-70.
60. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001;39:Suppl 1:55-66.
61. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000;164:3755-63.
62. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 2003;278:2043-50.
63. Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii: evidence for a unique gsc-1 subunit mediating beta-1,3-glucan deposition. J Biol Chem 2000;275:40628-34.
64. Schmatz DM, Romancheck MA, Pittarelli LA, et al. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A 1990;87:5950-4.
65. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semi-synthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985-9.
66. Thomas CF, Anders RA, Gustafson MP, Leof EB, Limper AH. Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue. Am J Respir Cell Mol Biol 1998;18:297-306.
67. Gustafson MP, Thomas CF Jr, Rusnak F, Limper AH, Leof EB. Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii. J Biol Chem 2001;276:835-43.
68. Kottom TJ, Thomas CF Jr, Mubarak KK, Leof EB, Limper AH. Pneumocystis carinii uses a functional cdc13 B-type cyclin complex during its life cycle. Am J Respir Cell Mol Biol 2000;22:722-31.
69. Fox D, Smulian AG. Mitogen-activated protein kinase Mkp1 of Pneumocystis carinii complements the slt2Delta defect in the cell integrity pathway of Saccharomyces cerevisiae. Mol Microbiol 1999;34:451-62.
70. Thomas CF Jr, Kottom TJ, Leof EB, Limper AH. Characterization of a mitogen-activated protein kinase from Pneumocystis carinii. Am J Physiol 1998;275:L193-L199.
71. Vohra PK, Puri V, Thomas CF Jr. Complementation and characterization of the Pneumocystis carinii MAPK, PCM. FEBS Lett 2003;551:139-46.
72. Thomas CF Jr, Vohra PK, Park JG, Puri V, Limper AH, Kottom TJ. Pneumocystis carinii BCK1 functions in a mitogen-activated protein kinase cascade regulating fungal cell-wall assembly. FEBS Lett 2003;548:59-68.
73. Fox D, Smulian AG. Mkp1 of Pneumocystis carinii associates with the yeast transcription factor Rlm1 via a mechanism independent of the activation state. Cell Signal 2000;12:381-90.
74. Kottom TJ, Kohler JR, Thomas CF Jr, Fink GR, Limper AH. Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeast. Infect Immun 2003;71:6463-71.
75. Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr. Pneumocystis carinii STE11, an HMG-box protein, is phosphorylated by the mitogen activated protein kinase PCM. Gene 2003;312:173-9.
76. Smulian AG, Sesterhenn T, Tanaka R, Cushion MT. The ste3 pheromone receptor gene of Pneumocystis carinii is surrounded by a cluster of signal transduction genes. Genetics 2001;157:991-1002.
77. Smulian AG, Ryan M, Staben C, Cushion M. Signal transduction in Pneumocystis carinii: characterization of the genes (pcg1) encoding the alpha subunit of the G protein (PCG1) of Pneumocystis carinii carinii and Pneumocystis carinii ratti. Infect Immun 1996;64:691-701.
78. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr. Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol 2003;29:232-8.
79. Kaneshiro ES, Rosenfeld JA, Basselin-Eiweida M, et al. The Pneumocystis carinii drug target S-adenosyl-L-methionine:sterol C-24 methyl transferase has a unique substrate preference. Mol Microbiol 2002;44:989-99.
80. Ye D, Lee CH, Queener SF. Differential splicing of Pneumocystis carinii f. sp. carinii inosine 5′-monophosphate dehydrogenase pre-mRNA. Gene 2001;263:151-8.
81. Ma L, Jia Q, Kovacs JA. Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother 2002;46:3101-3.
82. Shellito J, Suzara W, Blumenfeld W, Beek JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990;85:1686-93.
83. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice: natural history and pathobiology. Am J Pathol 1990;136:1173-86.
84. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999;104:1307-17.
85. Harmsen AG, Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990;172:937-45.
86. Beck JM, Harmsen AG. Lymphocytes in host defense against Pneumocystis carinii. Semin Respir Infect 1998;13:330-8.
87. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 1999;67:3452-60.
88. Beck JM, Liggitt HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991;59:3859-62.
89. Downing JF, Kachel DL, Pasula R, Martin WJ II. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun 1999;67:1347-52.
90. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17:Suppl 2:S416-S422.
91. Beck JM, Warnock ML, Curtis JL, et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 1991;5:186-97.
92. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991;351:155-8.
93. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997;99:2110-7.
94. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998;102:1332-44.
95. Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol 1993;150:3932-40.
96. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992;60:1279-84.
97. Kolls JK, Lei D, Vazquez C, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol 1997;16:112-8.
98. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996;98:50-61.
99. Brown GD, Gordon S. Immune recognition: a new receptor for beta-glucans. Nature 2001;413:36-7.
100. Vassallo R, Kottom TJ, Standing JE, Limper AH. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 2001;25:203-11.
101. Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995;151:1058-62.
102. Walzer PD. Attachment of microbes to host cells: relevance of Pneumocystis carinii. Lab Invest 1986;54:589-92.
103. Limper AH, Standing JE, Hoffman OA, Castro M, Neese LW. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993;61:4302-9.
104. Benfield TL, Prento P, Junge J, Vestbo J, Lundgren JD. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997;111:1193-9.
105. Beck JM, Preston AM, Wagner JG, et al. Interaction of rat Pneumocystis carinii and rat alveolar epithelial cells in vitro. Am J Physiol 1998;275:L118-L125.
106. Limper AH, Edens M, Anders RA, Leof EB. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 1998;101:1148-55.
107. Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WJ, II. 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 1992;99:143-9.
108. O'Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH. Surfactant protein D interacts with Pneumocystis cadnii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995;95:2699-710.
109. Beers MF, Atochina EN, Preston AM, Beck JM. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 1999;133:423-33.
110. Williams MD, Wright JR, March KL, Martin WJ II. Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Pespir Cell Mol Biol 1996;14:232-8.
111. Koziel H, Phelps DS, Fishman JA, Armstrong MY, Richards FF, Rose PM. Surfactant protein-A reduces binding and phagocytosis of pneumocystis carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol 1998;18:834-43.
112. Yong SJ, Vuk-Pavlovic Z, Standing JE, Crouch EC, Limper AH. Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun 2003;71:1662-71.
113. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001;69:758-64.